Alcoholic Hepatitis - Pipeline Review, H2 2018 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Sep 17, 2018--The “Alcoholic Hepatitis - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Alcoholic Hepatitis - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Alcoholic Hepatitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Alcoholic Hepatitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Alcoholic Hepatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 7, 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Alcoholic Hepatitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Featured News & Press Releases (2017-2018)DURECT Announces Patient Dosing in Phase 2a Trial of DUR-928 in Alcoholic Hepatitis Vital Therapies Announces VTL-308 Reaches Enrollment Target of 150 Subjects Vital Therapies Announces Characteristics of Early Subjects in VTL-308 Pivotal Study of ELAD System in Severe Alcoholic Hepatitis
Companies FeaturedDURECT Corp. Generon (Shanghai) Corp. Ltd. Gilead Sciences Inc. GRI Bio Inc. Immuron Ltd. Intercept Pharmaceuticals Inc. Promethera Biosciences SA Verlyx Pharma Inc. Vital Therapies Inc.
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/j72ff2/alcoholic?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180917005408/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Infectious Diseases Drugs,Liver and Kidney Disorders Drugs
INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/17/2018 09:48 AM/DISC: 09/17/2018 09:48 AM